Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.

Gao Q, Zhao YJ, Wang XY, Guo WJ, Gao S, Wei L, Shi JY, Shi GM, Wang ZC, Zhang YN, Shi YH, Ding J, Ding ZB, Ke AW, Dai Z, Wu FZ, Wang H, Qiu ZP, Chen ZA, Zhang ZF, Qiu SJ, Zhou J, He XH, Fan J.

Gastroenterology. 2014 May;146(5):1397-407. doi: 10.1053/j.gastro.2014.01.062. Epub 2014 Feb 4.

PMID:
24503127
2.

PTPN3 mutations and HBV may exert synergistic effects in the origin of the intrahepatic cholangiocarcinoma.

Cardinale V, Alvaro D.

Gastroenterology. 2014 Sep;147(3):719-20. doi: 10.1053/j.gastro.2014.05.046. Epub 2014 Jul 27. No abstract available.

PMID:
25075940
3.

Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2.

Nakanuma S, Tajima H, Okamoto K, Hayashi H, Nakagawara H, Onishi I, Takamura H, Kitagawa H, Fushida S, Tani T, Fujimura T, Kayahara M, Ohta T, Wakayama T, Iseki S, Harada S.

Int J Oncol. 2010 Apr;36(4):793-800.

PMID:
20198321
4.

Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.

Wu WR, Zhang R, Shi XD, Zhu MS, Xu LB, Zeng H, Liu C.

Oncol Rep. 2014 Jun;31(6):2515-24. doi: 10.3892/or.2014.3123. Epub 2014 Apr 2.

PMID:
24700253
5.

Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.

Lu D, Han C, Wu T.

Gastroenterology. 2011 Jun;140(7):2084-94. doi: 10.1053/j.gastro.2011.02.056. Epub 2011 Feb 24.

6.

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.

Gastroenterology. 2012 Apr;142(4):1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005. Epub 2011 Dec 13.

7.

Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.

Shen DY, Zhan YH, Wang QM, Rui G, Zhang ZM.

Liver Int. 2013 Jan;33(1):137-48. doi: 10.1111/liv.12014. Epub 2012 Nov 1.

PMID:
23121546
8.

High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.

Jin J, Ryu HS, Lee KB, Jang JJ.

PLoS One. 2014 Feb 28;9(2):e90247. doi: 10.1371/journal.pone.0090247. eCollection 2014.

9.

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM.

Gastroenterology. 2013 Apr;144(4):829-40. doi: 10.1053/j.gastro.2013.01.001. Epub 2013 Jan 4.

10.

High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.

Shi RY, Yang XR, Shen QJ, Yang LX, Xu Y, Qiu SJ, Sun YF, Zhang X, Wang Z, Zhu K, Qin WX, Tang ZY, Fan J, Zhou J.

Cancer. 2013 Mar 1;119(5):993-1003. doi: 10.1002/cncr.27788. Epub 2012 Nov 6.

11.

Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Wang Y, Hong Y, Li M, Long J, Zhao YP, Zhang JX, Li Q, You H, Tong WM, Jia JD, Huang J.

PLoS One. 2013 Dec 13;8(12):e82426. doi: 10.1371/journal.pone.0082426. eCollection 2013.

12.

A high level of integrin α6 expression in human intrahepatic cholangiocarcinoma cells is associated with a migratory and invasive phenotype.

Ding YB, Deng B, Huang YS, Xiao WM, Wu J, Zhang YQ, Wang YZ, Wu DC, Lu GT, Wu KY.

Dig Dis Sci. 2013 Jun;58(6):1627-35. doi: 10.1007/s10620-012-2524-6. Epub 2013 Jan 11.

PMID:
23306848
13.

Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.

Ding N, Che L, Li XL, Liu Y, Jiang LJ, Fan B, Tao JY, Chen X, Ji JF.

World J Gastroenterol. 2016 Feb 14;22(6):2071-80. doi: 10.3748/wjg.v22.i6.2071.

14.

Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.

Talabnin C, Janthavon P, Thongsom S, Suginta W, Talabnin K, Wongkham S.

Hum Pathol. 2016 Jun;52:47-54. doi: 10.1016/j.humpath.2015.12.027. Epub 2016 Feb 1.

PMID:
26980022
15.

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.

Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM.

Ann Surg Oncol. 2014 Nov;21(12):3827-34. doi: 10.1245/s10434-014-3828-x. Epub 2014 Jun 3.

16.

Prognostic significance of Capn4 overexpression in intrahepatic cholangiocarcinoma.

Zhang C, Bai DS, Huang XY, Shi GM, Ke AW, Yang LX, Yang XR, Zhou J, Fan J.

PLoS One. 2013;8(1):e54619. doi: 10.1371/journal.pone.0054619. Epub 2013 Jan 22.

17.

Downregulation of ROS-FIG inhibits cell proliferation, colony‑formation, cell cycle progression, migration and invasion, while inducing apoptosis in intrahepatic cholangiocarcinoma cells.

Deng G, Hu C, Zhu L, Huang F, Huang W, Xu H, Nie W.

Int J Mol Med. 2014 Sep;34(3):661-8. doi: 10.3892/ijmm.2014.1823. Epub 2014 Jun 27.

18.

Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.

Kosriwong K, Menheniott TR, Giraud AS, Jearanaikoon P, Sripa B, Limpaiboon T.

World J Gastroenterol. 2011 Mar 28;17(12):1631-41. doi: 10.3748/wjg.v17.i12.1631.

19.

miR-204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells.

Qiu YH, Wei YP, Shen NJ, Wang ZC, Kan T, Yu WL, Yi B, Zhang YJ.

Cell Physiol Biochem. 2013;32(5):1331-41. doi: 10.1159/000354531. Epub 2013 Nov 22.

20.

Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection.

Huang C, Tian Y, Peng R, Zhang C, Wang D, Han S, Jiao C, Wang X, Zhang H, Wang Y, Li X.

J Gastroenterol Hepatol. 2015 Feb;30(2):421-33. doi: 10.1111/jgh.12722.

PMID:
25168293

Supplemental Content

Support Center